VSTM (Verastem Inc) Utang jangka dawa

The business of Verastem, Inc. (VSTM) relies on the success of trials for agents against solid tumors and regulatory support. The price action, reaching 0.10, links operational achievements to a partnership strategy with global laboratories to develop RAS inhibitors. However, uncertainty regarding the final trial phases of avutometinib and the need for new equity offerings due to liquidity shortages create significant financial threats.

This indicator aggregates all financial obligations with maturities exceeding twelve months, measuring the issuer's long-term debt load and overall solvency. For Verastem, Inc. (VSTM), borrowings fund costly oncology research until the company secures monopoly pricing power; therefore, the company's long-term debt trajectory serves as an indicator of its financial runway before its drugs enter the market.